Current Neurology and Neuroscience Reports

, Volume 11, Issue 1, pp 52–60

Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel


DOI: 10.1007/s11910-010-0157-8

Cite this article as:
Donohue, M.M. & Tirschwell, D.L. Curr Neurol Neurosci Rep (2011) 11: 52. doi:10.1007/s11910-010-0157-8


Our knowledge of the pharmacogenetics of warfarin and clopidogrel continues to expand as we learn more about the individual genetic variations that contribute to the drugs’ efficacy and toxicity. We aim to review the recent developments in the field and discuss the clinical implications for the treatment of ischemic stroke patients. Despite recent advances, there is still insufficient data to suggest that routine genetic testing improves outcomes in patients treated with warfarin or clopidogrel for prevention of stroke.


PharmacogeneticsWarfarinClopidogrelTestingPrimary stroke preventionSecondary stroke preventionPolymorphismResistanceVariantAnticoagulationPlatelet responseDrug responseSafetyCYP2C19CYP2C9VKORC1Treatment algorithmABCB1P2RY12

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of NeurologyHarborview Medical CenterSeattleUSA